August 17, 2020 10:59 AM EDTUpdated 01:05 PM

Ned Sharpless' 'brainchild' nabs a speedy FDA review for small cell lung cancer drug

Nicole DeFeudis

Editor

It was animal data on G1 Therapeutics’ oncology drug trilaciclib that originally attracted current CEO Mark Velleca to the company six years ago. And now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ned Sharpless' 'brainchild' nabs a speedy FDA review for small cell lung cancer drug

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Ned Sharp­less' 'brain­child' nabs a speedy FDA re­view for small cell lung can­cer drug

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Ned Sharpless' 'brainchild' nabs a speedy FDA review for small cell lung cancer drug